CARSON CITY, Nev., Dec. 30 /PRNewswire-FirstCall/ -- Niusule Biotech Corp., a Nevada corporation formed on April 8, 2008, announced today that its shares of common stock will begin trading on the OTC Bulletin Board under the symbol "NIUS" on December 30th, 2008.
For a NIUS quote, visit: http://finance.yahoo.com/q?s=NIUS.OB
"Our main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp by manufacturing and selling biopharmaceutical and health food," said Qinghua Hu, Chairman of Niusule Biotech Corp. "We believe our public listing is a signal of Niusule Biotech Corp.'s maturity as a company. I would like to thank Niusule Biotech Corp.'s partners, employees and shareholders for their respective roles in contributing to our success."
In a meeting with employees, directors, and shareholders, Hu discussed Niusule Biotech Corp. goals and priorities as a publicly traded entity including:
"As we are in our initial stages of growth, we provide both small and institutional investors opportunities to invest in China's health food industry," said Hu. "The move to the OTC Bulletin Board positions the company to benefit from greater visibility and liquidity."
About Niusule Biotech Corp.
Founded in 2008, Niusule Biotech Corp.'s main business will be operated in China through our subsidiary Zhejiang Baitai Bioengineering Corp. Niusule Biotech Corp. is trying to build a bridge between the USA and China in the health food industry and bioengineering industry by accessing the talent pools in both countries and by applying the mature technologies and high quality standards of the USA to its business model in China.
For more information about Niusule Biotech Corp., visit http://www.niusule.com.
This news release contains forward-looking statements. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks described in the company's filings with the SEC.
CONTACT: Joe Zhou of Niusule Biotech Corp., 1-866-348-0645,
joe@niusule.com
Web site: http://www.niusule.com/
